UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2004
Callisto Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 333-63474 13-3894575
(State or other jurisdiction (Commission IRS Employer
of incorporation or organization) File Number) Identification No.)
420 Lexington Avenue, Suite 1609
New York, New York 10170
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 297-0010
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
/ / Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
/ / Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
/ / Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
/ / Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS.
On September 7, 2004, Callisto Pharmaceuticals, Inc., a Delaware
corporation ("Callisto"), issued a press release announcing that it had entered
into a license agreement with The University of Texas M. D. Anderson Cancer
Center for the licensing of Annamycin, an anthracycline drug for cancer therapy.
A copy of the press release is attached hereto as Exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit Number Description
10.1 Patent and Technology License Agreement
dated August 12, 2004 by and between The
Board of Regents of the University of Texas
System, on behalf of The University of Texas
M. D. Anderson Cancer Center and Callisto
Pharmaceuticals, Inc.*
99.1 Press Release dated September 7, 2004.
* Confidential treatment has been requested as to certain portions of this
exhibit which portions have been omitted and filed separately with the
Securities and Exchange Commission.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: September 7, 2004
CALLISTO PHARMACEUTICALS, INC.
By: /s/ Gary S. Jacob
-----------------
Gary S. Jacob, Ph.D.
Chief Executive Officer